|
Collaboration Agreement (Details Textual) (USD $)
|
1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 6 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2009
|
Jun. 30, 2012
|
Jun. 30, 2011
|
Jun. 30, 2012
|
Jun. 30, 2011
|
Dec. 31, 2011
|
Dec. 31, 2009
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Minimum [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Maximum [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Collaboration Agreement [Member]
|
Jun. 30, 2012
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2011
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2011
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries [Member]
|
Dec. 20, 2009
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Collaboration Agreement [Member]
Minimum [Member]
TEVA Pharmaceutical Industries [Member]
|
Jun. 30, 2012
Collaboration Agreement [Member]
Maximum [Member]
TEVA Pharmaceutical Industries [Member]
|
|
| Collaboration Agreement (Textual) [Abstract] | ||||||||||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | $ 50,000,000 | ||||||||||||||||
| Maximum amount receivable | 370,000,000 | 370,000,000 | ||||||||||||||||
| Equity investment | 14,000 | 14,000 | 10,000 | 10,000,000 | 10,000,000 | |||||||||||||
| Share premium | 20.00% | |||||||||||||||||
| Common shares, purchase price | $ 12.00 | $ 12.00 | $ 37.38 | $ 37.38 | ||||||||||||||
| Common shares purchased | 267,531 | |||||||||||||||||
| Research and development | 6,326,000 | 5,409,000 | 11,408,000 | 10,262,000 | 10,000,000 | |||||||||||||
| Payment related to license agreement | 300,000 | |||||||||||||||||
| Percentage of milestone payments required to be paid to third party | 31.00% | |||||||||||||||||
| Percentage of net sales required to be paid as royalty to third party | 4.88% | 8.00% | ||||||||||||||||
| Direct and indirect development costs | 30,000,000 | |||||||||||||||||
| Period of authorization change | 90 days | |||||||||||||||||
| Revenue | 2,400,000 | 1,900,000 | 3,700,000 | 3,100,000 | ||||||||||||||
| Deferred collaboration revenue | 15,400,000 | 15,400,000 | ||||||||||||||||
| Revenue reimbursable on cash basis | 500,000 | |||||||||||||||||
| Royalties at percentage rates ranging | Mid-teens to mid-twenties on net sales | |||||||||||||||||
| Terminate of collaboration agreement | 3 months | 6 months | ||||||||||||||||
| Expiration of royalties | 10 years | |||||||||||||||||
| Long-term purchase commitment, milestones | No milestones were due | |||||||||||||||||
| Royalty Expense | $ 0 | |||||||||||||||||
| Collaboration Agreement (Additional Textual) [Abstract] | ||||||||||||||||||
| Average premium period | 30 days | |||||||||||||||||